USD10
VRDN Shares
About Viridian TherapeuticsViridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.

USD10
VRDN Shares
About Viridian TherapeuticsViridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.

Stats

TRADING WINDOW

Open

CLOSES AT

8:00 PM GMT+0

MARKET CAP

$1.66B

OPEN PRICE

$17.31

LOW (1Y)

$9.90

HIGH (1Y)

$34.29

LOW (24H)

$17.28

HIGH (24H)

$17.72

VOLUME (24H)

$750.21K

45.25%

Price history

Time
Price
Change
Today
$17.31
0.40%
1 Day
$17.43
0.29%
1 Week
$16.63
4.51%
1 Month
$17.22
0.93%
1 Year
$14.55
19.45%
Past performance is not a reliable indicator of future results.

Discover more

Legal
Information is provided for informational purposes only, and is not investment advice. This is not an invitation, inducement or recommendation to buy any particular asset, or to employ any particular investment strategy. Coinbase makes no representation as to the accuracy, suitability or validity of any information provided.All ticker names are trademarks of their respective holders. Any ticker reference does not imply affiliate with or endorsement by a third-party. Real-time prices are sourced from third parties, but not from all markets. Source: Nasdaq Last Sale. Morningstar data ©2026.